Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 592

1.

Approaching clinical proteomics: current state and future fields of application in cellular proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tárnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Wagener C, Wagner O, Schmitz G.

Cytometry A. 2009 Oct;75(10):816-32. doi: 10.1002/cyto.a.20779. Review.

2.

Approaching clinical proteomics: current state and future fields of application in fluid proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G.

Clin Chem Lab Med. 2009;47(6):724-44. doi: 10.1515/CCLM.2009.167. Review.

PMID:
19527139
3.

Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.

Calvo KR, Liotta LA, Petricoin EF.

Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. Review.

PMID:
16222423
4.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

[Preanalytical guidelines for clinical proteomics investigation of biological fluids].

Lehmann S, Roche S, Allory Y, Barthelaix A, Beaudeux JL, Berger F, Betsou F, Borg J, Dupuy A, Garin J, Quillard M, Lizard G, Peoc'h K, Riviere M, Ducoroy P.

Ann Biol Clin (Paris). 2009 Nov-Dec;67(6):629-39. doi: 10.1684/abc.2009.0374. French.

6.

Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.

Aardema MJ, MacGregor JT.

Mutat Res. 2002 Jan 29;499(1):13-25. Review.

PMID:
11804602
7.

Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.

Phan JH, Quo CF, Wang MD.

Prog Brain Res. 2006;158:83-108. Review.

PMID:
17027692
8.

Proteomics in cancer.

Reymond MA, Schlegel W.

Adv Clin Chem. 2007;44:103-42. Review.

PMID:
17682341
9.
10.
11.

The molecular make-up of a tumour: proteomics in cancer research.

Kolch W, Mischak H, Pitt AR.

Clin Sci (Lond). 2005 May;108(5):369-83. Review.

PMID:
15831087
12.

[Present possibilities and future development of clinical proteomics].

Lehmann S, Dupuy A, Peoc'h K, Roche S, Baudin B, Quillard M, Berger F, Briand G, Chwetzoff S, Dine G, Gonzalo P, Dastugue B, Sève M, Siest G, Beaudeux JL.

Ann Biol Clin (Paris). 2007 Sep-Oct;65(5):463-71. Review. French.

13.

Oncoproteomics: current trends and future perspectives.

Cho WC, Cheng CH.

Expert Rev Proteomics. 2007 Jun;4(3):401-10. Review.

PMID:
17552924
14.

Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry.

Ahmed FE.

J Sep Sci. 2009 Mar;32(5-6):771-98. doi: 10.1002/jssc.200800622. Review.

PMID:
19219839
15.

Phosphoproteomics by mass spectrometry and classical protein chemistry approaches.

Salih E.

Mass Spectrom Rev. 2005 Nov-Dec;24(6):828-46. Review.

PMID:
15538747
16.

Multiplex proteomic approaches to sepsis research: case studies employing new technologies.

Heuer JG, Cummins DJ, Edmonds BT.

Expert Rev Proteomics. 2005 Oct;2(5):669-80. Review.

PMID:
16209647
17.

Proteomics: new technologies and clinical applications.

Latterich M, Abramovitz M, Leyland-Jones B.

Eur J Cancer. 2008 Dec;44(18):2737-41. doi: 10.1016/j.ejca.2008.09.007. Review.

PMID:
18977654
18.

Proteomics: current techniques and potential applications to lung disease.

Hirsch J, Hansen KC, Burlingame AL, Matthay MA.

Am J Physiol Lung Cell Mol Physiol. 2004 Jul;287(1):L1-23. Review.

19.

How industry is approaching the search for new diagnostic markers and biomarkers.

Zolg JW, Langen H.

Mol Cell Proteomics. 2004 Apr;3(4):345-54. Review.

20.

Target identification and validation in drug discovery: the role of proteomics.

Kopec KK, Bozyczko-Coyne D, Williams M.

Biochem Pharmacol. 2005 Apr 15;69(8):1133-9.

PMID:
15794933
Items per page

Supplemental Content

Support Center